Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Recombinant virus encoding one or more heterologous proteins...
Reexamination Certificate
2007-10-09
2007-10-09
Chen, Stacy B. (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Recombinant virus encoding one or more heterologous proteins...
C424S204100, C536S023100, C536S023720, C435S069100, C435S440000, C435S455000
Reexamination Certificate
active
10808964
ABSTRACT:
The present invention relates to infectious DNA clones, infectious chimeric DNA clones of porcine circovirus (PCV), vaccines and means of protecting pigs against viral infection or postweaning multisystemic wasting syndrome (PMWS) caused by PCV2. The new chimeric infectious DNA clone and its derived, avirulent chimeric virus are constructed from the nonpathogenic PCV1 in which the immunogenic ORF gene of the pathogenic PCV2 replaces a gene of the nonpathogenic PCV1, preferably in the same position. The chimeric virus advantageously retains the nonpathogenic phenotype of PCV1 but elicits specific immune responses against the pathogenic PCV2. The invention further embraces the immunogenic polypeptide expression products. In addition, the invention encompasses two mutations in the PCV2 immunogenic capsid gene and protein, and the introduction of the ORF2 mutations in the chimeric clones.
REFERENCES:
patent: 6217883 (2001-04-01), Allan et al.
patent: 6287856 (2001-09-01), Poet et al.
patent: 6368601 (2002-04-01), Allan et al.
patent: 6391314 (2002-05-01), Allan et al.
patent: 6497883 (2002-12-01), Bublot et al.
patent: 6703023 (2004-03-01), Jestin et al.
patent: 6943152 (2005-09-01), Audonnet et al.
patent: 2002/0055189 (2002-05-01), Bernhardt et al.
patent: 2002/0146431 (2002-10-01), Allan et al.
patent: 2002/0177216 (2002-11-01), Liu et al.
patent: 2003/0003112 (2003-01-01), Audonnet et al.
patent: 2 772 047 (1999-06-01), None
patent: 99/18214 (1999-04-01), None
patent: WO 99/29871 (1999-06-01), None
patent: 99/45956 (1999-09-01), None
patent: 00/01409 (2000-01-01), None
patent: 00/77216 (2000-12-01), None
patent: WO 00/77188 (2000-12-01), None
patent: 01/16330 (2001-03-01), None
patent: 01/83737 (2001-11-01), None
patent: 01/96377 (2001-12-01), None
patent: 02/077210 (2002-10-01), None
patent: 02/102999 (2002-12-01), None
Sequence alignment of SEQ ID No. 2 against Genseq database accession No. AAL57177, submitted Oct. 27, 2003 by applicant in WO 2003049703-A2.
Fenuax et al. Journal of Virology. 2004; 78 (12): 6297-6303.
Krakowka et al. Viral Immunology. 2002; 15 (4): 567-582.
M. Fenaux et al., Genetic Characterization of Type 2 Porcine Circovirus (PCV-2) from Pigs with Postweaning Multisystemic Wasting Syndrome in Different Geographic Regions of North America and Development of a Differential PCR-Restriction Fragment Length Polymorphism Assay To Detect and Differentiate between Infections with PCV-1 and PCV-2, J. Clin. Microbiol. 38 (7):2494-2503 (Jul. 2000).
P. Nawagitgul et al., “Open reading frame 2 of porcine circovirus type 2 encodes a major capsid protein,” Journal of General Virology 81:2281-2287 (2000).
D. Mahé´ et al., “Differential recognition of ORF2 protein from type 1 and type 2 porcine circoviruses and identification of immunorelevant epitopes,” Journal of General Virology 81:1815-1824 (2000).
S. Lustig et al., “Molecular Basis of Sindbis Virus Neurovirulence in Mice,” Journal of Virology 62(7):2329-2336 (Jul. 1988).
M. Caggana et al., “Identification of a Single Amino Acid Residue in the Capsid Protein VP1 of Coxsackievirus B4 That Determines the Virulent Phenotype,” Journal of Virology 67(8):4797-4803 (Aug. 1993).
Liu et al., “Bacterial Expression of an Immunologically Reactive PCV2 ORF2 Fusion Protein,” Protein Expression and Purification, 2001, 21:115-120.
Pogranichnyy et al., “Characterization of Immune Response of Young Pigs to Porcine Circovirus Type 2 Infection,” Viral Immunology, 2000, 13(2):143-153.
Meehan et al., “Characterization of novel circovirus DNAs associated with wasting syndromes in pigs,” J. Gen. Virology, SGM, Sep. 1998, 79(9):2171-2179, XP002090386.
Fenaux et al., “Immunogenicity and Pathogenicity of Chimeric Infectious DNA Clones of Pathogenic Porcine Circovirus Type 2 (PCV2) and Nonpathogenic PCV1 in Weanling Pigs,” J. Virology, Oct. 2003, 77(20):11232-11243.
Fenaux et al., “A Chimeric Procine Circovirus (PCV) with the Immunogenic Capsid Gene of the Pathogenic PCV Type 2 (PCV2) in Cloned into the Genomic Backbone of the Nonpathogenic PCV1 Induces Protective Immunity Against PCV2 Infection in Pigs,” J. Virology, Jun. 2004, 78(12):6297-6303.
Fenaux Martijn
Halbur Patrick G.
Meng Xiang-Jin
Chen Stacy B.
Iowa State University & Research Foundation, Inc.
Mandel Adley F.
Rosenblum Anne M.
Virginia Tech Intellectual Properties Inc.
LandOfFree
Chimeric infectious DNA clones, chimeric porcine... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Chimeric infectious DNA clones, chimeric porcine..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Chimeric infectious DNA clones, chimeric porcine... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3887387